BOARD OF DIRECTORS

Mary Campbell, M.B.A.

Mary Campbell is a Managing Director and Founder of EDF Ventures. Mary received her M.B.A. from the University of Michigan; her M.A. in Special Education from Fairfield University; and her B.A. in English from the University of Michigan. She has been an active investor both in healthcare and information technology companies for over 20 years.

Currently, Mary sits on the boards of HandyLab, Health Care Solutions, Rhevision Technology, ValenTx and is a board observers for Cerenis Therapeutics, The Echo Group, and QuadraSpec. In 1997, Mary led the firm’s most successful transaction, Pixelworks, a leader of system-on-a-chip integrated circuits for the advanced display market which went public in 2000 (NASDAQ: PXLW). She has been the lead investor for six of the firm’s investments in healthcare companies and five of its investments in information technology companies.

Mary is active with The Stephen M. Ross School of Business at the University of Michigan and currently serves as an advisor to the Zell Lurie Institute for Entrepreneurial Studies as well as its student-run venture activity, the Wolverine Venture Fund. She is an advisor to the University of Michigan’s Life Science Institute. She is a member of the Steering Committee for the Michigan Strategic Economic Investment and Commercialization Board, a Statewide initiative to foster research and commercialization. Mary is also President of the Michigan Venture Capital Association, the State’s premier public policy advocate for the private equity/venture capital industry.

David Canter, MB, Ch.B, FRCS

David Canter is a graduate of Cambridge and Liverpool Universities and is currently Senior Vice President of Pfizer Global Research & Development, and Site Director of Michigan Laboratories. Dr. Canter joined Warner-Lambert in 1984. He became the Senior Director of Cardiovascular Clinical Development in 1989, and Vice President of Drug Development in 1992. From 1997-2000, he was Director of the Institut de Recherche et Development, Jouveinal in Paris. After the merger of Pfizer & Warner-Lambert in 2000, he assumed the position of Site Director of Ann Arbor Laboratories. After the merger with Pharmacia in 2003, he assumed his current position. Over his distinguished career, he has been involved with the clinical development of many drugs, including, Lopid, Accupril, and Quinapril. He was also the project leader for the development of Lipitor from early phase 2 through the product launch. Dr. Canter, a Fellow of the Royal College of Surgeons, and a Member of the Faculty of Pharmaceutical Physician

Gary D. Glick, Ph.D.

Dr. Gary Glick, the scientific founder of Lycera Corp., obtained his Ph.D. from Columbia University in 1988, studying organic chemistry under the direction of W. Clark Still. He then completed a National Institutes of Health postdoctoral fellowship at Harvard University where he studied bio-organic chemistry in the laboratory of Jeremy R. Knowles. In 1990, Dr. Glick joined the chemistry faculty at the University of Michigan in Ann Arbor, where he presently holds the Werner E. Bachmann chair in chemistry, is a professor in the Department of Biological Chemistry at the University of Michigan Medical School, and is a member of the training faculty for the interdepartmental Immunology and Medicinal Chemistry doctoral programs. He is also the founder and director of the Chemical Biology Doctoral Program at Michigan. Dr. Glick’s research interests are in drug discovery and development for autoimmune diseases and cancer; chemical-induced apoptosis; nucleic acid structure, folding and recognition; and molecular recognition of nucleic acids by proteins.

Dr. Glick has served and continues to serve on numerous boards and committees, including the Bioorganic & Natural Products Chemistry Study Section of the National Institutes of Health and the Scientific Advisory Board of the National Arthritis Foundation, Michigan Chapter. He serves on several editorial boards, is Editor-in-Chief of Biopolymers, a leading journal publishing in the areas of biochemistry and biophysics, and is a counselor to the American Chemical Society Division of Biological Chemistry.

Dr. Glick’s scientific contributions have been recognized with a number of different awards including, an Arthritis Investigator Award from the National Arthritis Foundation, a Junior Faculty Research Award from the American Cancer Society, a Young Investigator Award from the National Science Foundation, a Camille Dreyfus Teacher-Scholar Award, a Research Fellowship from the Alfred P. Sloan Foundation, and two Research Excellence Awards from the University of Michigan.

David Hoffman, M.B.A. (Board Advisor)

Mr. Hoffman has over 20 years experience in finance, investing and board advisement. David was COO for Universal Marketing, a nationwide book retailer and wholesaler from 1990 to 1993. He then went on to a full time career at two major Wall Street Firms, Deutsche Bank and Merrill Lynch. He founded with several Wall Street colleagues, Grassroots Venture Capital, the management company for several angel funds in 1996. Those funds have made over 15 early stage investments in the last 10 years in Biotechnology and Internet Services. David served as advisor or Board member to many of these companies and their executive managers. Grassroots was a founding investor in Orasure, which went public in 2001. Computer Associates purchased Ilumin, another founding investment, in 2005. David has an Economics Degree from Rutgers University and an M.B.A. from Columbia University.

Tim Mayleben, M.B.A.

Timothy M. Mayleben is President & Chief Operating Officer and a Director of NightHawk Radiology Holdings, Inc., a leading provider of radiology services to radiology groups across the U.S. Prior to this he was an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors. Mr. Mayleben was formerly the Chief Operating Officer of Esperion Therapeutics, now a division of Pfizer Global Research & Development. He joined Esperion in late 1998 as Chief Financial Officer. While at Esperion, Mr. Mayleben led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in December 2003. Prior to joining Esperion, Mr. Mayleben held various senior and executive management positions at Transom Technologies, Inc., now part of Electronic Data Systems, Inc., and Applied Intelligent Systems, Inc., which was acquired by Electro-Scientific Industries, Inc. in 1997. Mr. Mayleben holds a Masters of Business Administration, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Business Administration degree from the University of Michigan Ross School of Business. He is also on the Board of Directors of Aastrom Biosciences, Inc. and on the Advisory Board for the Wolverine Venture Fund.